ARTICLE | Top Story
Novartis says CAR T on track
October 25, 2016 7:00 AM UTC
Novartis AG (NYSE:NVS; SIX:NOVN) on Tuesday said it remains on track to submit a BLA to FDA early next year for its CTL019 chimeric antigen receptor (CAR) T cell therapy to treat pediatric acute lymphoblastic leukemia (ALL). A second submission for diffuse large B cell lymphoma (DLBCL) is slated for 2H17.
On a conference call to announce 3Q16 earnings, CEO Joe Jimenez said the company's August decision to integrate its stand-alone cell and gene therapy unit into its oncology business would lower overhead while improving the unit's development, manufacturing and commercial capabilities as CTL019 prepares to launch. ...